Consun Pharmaceutical Group Limited has released its Interim Report 2026 in both English and Chinese on 24 September 2026. The document is now accessible through the Hong Kong Stock Exchange’s website (www.hkexnews.hk) and the company’s website (www.chinaconsun.com).

Key points:

• Transition to e-communication – In line with HKEX Listing Rule 2.07A, Consun Pharmaceutical will distribute all future corporate communications—ranging from annual and interim reports to circulars and proxy forms—exclusively in electronic format via the company and HKEX websites.

• Shareholder action required – Registered shareholders are encouraged to provide a functional email address. This can be done by scanning the personalised QR code on the enclosed reply form or by returning the form to Computershare Hong Kong Investor Services Limited, the company’s Hong Kong branch share registrar.

• Printed copies on request – Shareholders who experience difficulty accessing electronic documents, or who prefer hard copies, may request printed versions free of charge by emailing consunpharma.ecom@computershare.com.hk or writing to the branch share registrar. Such requests remain valid for one year unless revoked earlier.

• Consequences of non-action – Without a valid email address on record, shareholders will not receive electronic notifications of new corporate communications and must proactively check the company and HKEX websites. Actionable corporate communications—those requiring shareholder instructions—will continue to be dispatched in printed form by default.

• Contact details – Enquiries can be directed to the branch share registrar at +852 2862 8688 during business hours (09:00–18:00, Hong Kong time, Monday to Friday, excluding public holidays).

Chairman An Meng signed the notice on behalf of the board, underscoring the group’s commitment to operational efficiency and enhanced shareholder communication through digital channels.